Published in J Hepatol on December 01, 2003
Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol (2013) 3.25
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.90
Steatosis in chronic hepatitis C: why does it really matter? Gut (2006) 2.10
The history of the "natural history" of hepatitis C (1968-2009). Liver Int (2009) 1.63
Hepatitis C virus and type 2 diabetes. World J Gastroenterol (2009) 1.57
Insulin resistance and hepatitis C. World J Gastroenterol (2006) 1.33
Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol (2006) 1.09
Molecular mechanisms of liver fibrosis in HIV/HCV coinfection. Int J Mol Sci (2014) 1.01
Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis. Mol Med (2011) 0.95
Targeting host factors: a novel rationale for the management of hepatitis C virus. World J Gastroenterol (2009) 0.93
Hepatic steatosis: a benign disease or a silent killer. World J Gastroenterol (2008) 0.92
New treatments for chronic hepatitis C. Korean J Hepatol (2010) 0.89
Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance. PPAR Res (2009) 0.83
Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci (2009) 0.83
Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol (2014) 0.82
Occlusion of portosystemic shunts improves hyperinsulinemia due to insulin resistance in cirrhotic patients with portal hypertension. J Gastroenterol (2013) 0.80
NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci (2016) 0.80
Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies. World J Hepatol (2014) 0.79
Relation of insulin resistance and liver fibrosis progression in patients with chronic hepatitis C virus infection. Int J Health Sci (Qassim) (2009) 0.77
Skin tags and acanthosis nigricans in patients with hepatitis C infection in relation to insulin resistance and insulin like growth factor-1 levels. Indian J Dermatol (2012) 0.77
Hepatitis C virus in Mexican Americans: a population-based study reveals relatively high prevalence and negative association with diabetes. Epidemiol Infect (2015) 0.77
Treatment uptake of patients with chronic hepatitis C: can we expect and do more? Dig Dis Sci (2010) 0.77
Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C. J Clin Transl Hepatol (2014) 0.76
Association of hepatitis C virus infection and diabetes. World J Gastroenterol (2009) 0.76
Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease. World J Gastroenterol (2016) 0.75
Diabetes Mellitus is Associated With Higher Risk of Developing Decompensated Cirrhosis in Chronic Hepatitis C Patients. J Clin Gastroenterol (2017) 0.75
Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology (2009) 5.87
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Viral hepatitis B. Lancet (2003) 4.86
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem (2004) 3.45
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology (2008) 3.15
Truth survival in clinical research: an evidence-based requiem? Ann Intern Med (2002) 2.87
Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology (2009) 2.79
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology (2013) 2.62
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol (2005) 2.62
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS (2003) 2.58
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol (2009) 2.39
Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology (2003) 2.23
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol (2003) 2.19
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol (2004) 2.19
Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial. Ann Intern Med (2009) 2.16
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology (2010) 2.13
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology (2011) 2.11
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology (2009) 2.10
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology (2005) 2.08
Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology (2004) 2.08
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol (2007) 2.08
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology (2002) 2.06
Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible? J Hepatol (2003) 2.04
Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology (2002) 2.02
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology (2002) 1.94
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.86
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem (2007) 1.84
Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology (2009) 1.84
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol (2013) 1.84
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem (2006) 1.78
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology (2005) 1.76
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology (2011) 1.71
Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. Hepatology (2008) 1.70
Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. J Cyst Fibros (2013) 1.66
Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis. Clin Gastroenterol Hepatol (2012) 1.65
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol (2005) 1.63
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol (2006) 1.63
Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferred. J Hepatol (2010) 1.60
Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther (2014) 1.60
Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol (2004) 1.57
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol (2005) 1.54
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer (2007) 1.51
High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats. Hepatology (2007) 1.50
Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol (2007) 1.49
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.47
HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol (2011) 1.47
Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur J Gastroenterol Hepatol (2004) 1.44
Liver biopsy: the best standard...when everything else fails. J Hepatol (2009) 1.43
Lamivudine and HBV-associated nephropathy. Nephrol Dial Transplant (2005) 1.40
Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology (2002) 1.40
Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants. J Virol (2006) 1.39
Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med (2004) 1.39
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology (2002) 1.36
Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol (2005) 1.33
Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology (2007) 1.33
Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol (2007) 1.31
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS (2002) 1.30
Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. Am J Trop Med Hyg (2010) 1.28
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol (2005) 1.27
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology (2004) 1.26
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer (2008) 1.25
A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol (2002) 1.25
FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol (2008) 1.21
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther (2004) 1.19
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol (2010) 1.16
Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol (2002) 1.16
Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. Hepatology (2006) 1.15
Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology (2006) 1.15
Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard. J Hepatol (2013) 1.15
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology (2010) 1.14
Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? Gastroenterology (2005) 1.13
Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS One (2008) 1.13